Salarius Pharmaceuticals, Inc. (SLRX) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Solaris Pharmaceuticals Second Quarter 2022 Financial Results and Business Update Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then 2. Please note, this event is being recorded. I would now like to turn the conference over to Kim Golodets with LHA Investor Relations. Kim, please go ahead. Thank you. This is Kim Golodets, Senior Vice President Principal with LHA Investor Relations. Thank you all for participating in today's call. Joining me from Solaris Pharmaceuticals are David Arthur, Director and Chief Executive Officer, and Mark Rosenblum, Chief Financial Officer. In addition, Dr. Daniela Santay-Esteban, Director of Protein Degradation Development, will be available for Q&A. During this call, Solaris will be making forward-looking statements about operating metrics, future expectations, plans, events, and circumstances, including statements about its strategy, future operations, the development and effectiveness of its investigational drug candidates, Seclodemstat and SP3164, as well as its targeted protein degradation program and expectations regarding its capital allocation and cash resources. These statements are based on Solaris' current expectations, and you should not place undue reliance on these statements. Actual results may differ materially due to risks and uncertainties, including those detailed in the risk factor section of the company's annual report on Form 10-K for the year ended December 31, 2021. and subsequent quar...